Rheumatoid Arthritis (RA) is a chronic autoimmune disorder that primarily affects the joints. In this condition, the immune system, which is meant to protect the body from foreign invaders like bacteria and viruses, mistakenly attacks the synovium—the lining of the membranes that surround the joints. This immune system response results in inflammation that can lead to joint damage, pain, and swelling.
D&H National Research Centers is currently conducting a study on Rheumatoid Arthritis. As a prominent leader in clinical research in Florida, we are committed to advancing medical knowledge and patient care.
Inclusion Criteria:
If you want to participate in this study, you must meet the following criteria:
​
-
Male or female subjects aged from 18 years old.
-
Diagnosis of moderate to severe RA.
-
Weight > 40 kg.
-
Patients must be methotrexate-inadequate responders.
Exclusion Criteria:
You are not eligible for participation in this study if:
-
History of treatment with Natrunix for any reason.
-
Any active, chronic, or recurrent infections. (e.g., ongoing bacterial, viral, or fungal
infection). -
Comorbid severe psychiatric illness and/or complicated social situations that would limit compliance with study requirements.
-
Patients must not have received any biological therapy including anakinra, rilonacept,
canakinumab, adalimumab, certolizumab, etanercept, golimumab, infliximab, abatacept,
tocilizumab, sarilumab, and biosimilars within 8 weeks prior to randomization.
D&H National Research Centers is a leading medical trial center located in Florida.
​
If you are interested in joining our Rheumatoid Arthritis medical trial or have questions about the study, please don't hesitate to reach out to us. We are here to provide you with all the information and support you need, please fill the form or contact us by phone: (786) 375-6210